Pharmafile Logo

Focus on Rare Diseases

As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond.

- PMLiVE
The US government passed the Orphan Drug Act in 1983, and it was subsequently adopted in other key markets, most notably in Japan in 1993 and the European Union in 2000. Growth in this sector has remained around 12% annually, which is more than double that experienced in the general drug market. According to the 2015 Orphan Drug Report, worldwide orphan drug sales will reach $178 billion by 2020 and will account for 20% of all prescription drug sales by 2020*. 

The trend is clear: as science and technology advances, and the rise of the internet and social media enables patients and researchers to gather and share information more effectively, we are seeing treatments for rare diseases that only a few years ago would have led to an early death. 

Alison Cantle, Rare Disease Business Unit Director at Lucid Group, explains what this means for medical education agencies: “As pharmaceutical organisations focus on personalised medicine, the need for rare disease expertise in their medical education agencies is paramount. Lucid recognised this and structured its business last year to create a unit specialising in rare diseases.” 

Within this unit, Lucid Group had recruited a team of highly skilled medical writers who combine a deep and robust understanding of the science with experience of working with rare disease specialists across the globe.

“Our rare disease team understands the cornerstones of rare disease education and what makes it different from other therapy areas. It is essential to build networks and enable best practice sharing,” Alison explains. “And in rare disease, more so than in any other therapy area, the choice of agency is crucial, as often it is your agency who represents your organisation at the communication level – so its voice has to be your voice.” 

Patients who have a rare disease face difficulty in every step of medical care, including diagnosis, treatment and preserving quality of life. Sometimes, patients go years without receiving the correct diagnosis for their condition. So raising awareness, improving time to diagnosis, getting patients to the right care, and improving family and emotional support and reimbursement are just some of the areas where medical education agencies can support pharma clients. 

Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease, cystinosis and PKU.  For further information about working with Lucid’s Rare Disease Business Unit, please call Alison on 01494 552078 or email alison@lucid-uk.com. 

* EvaluatePharma Orphan Drug Report 2015

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Why Editing Matters – Finding the best

In the most recent issue of Why Editing Matters, produced by the Chartered Institute of Editing and Proofreading (CIEP), Liz Jennings, associate editorial director of the Centre of Medical Editing...

Nurses on the frontline – World Health Day 2020

Today, 7 April, is World Health Day ­­– the day to celebrate the work of nurses and midwives and remind world leaders of the critical role they play in keeping...

We’re Celebrating Ten Magical Years for Ify at Lucid Group

​Today we are celebrating a very important work anniversary for Ify Onyeaso. Ify joined Lucid 10 years ago, quickly becoming a core member of the then, fledgeling business. Over the...

Today’s reality: how to make social distancing work in medcomms

At Lucid, we don’t just want to cope with COVID-19.The current situation certainly presents an unprecedented challenge to delivering medical education. The daily update of cancellations and postponements has become...

Remote Working: Join the Revolution Workshop

As a nation, we are still coming to terms with our ‘new normal’, where social distancing has forced us out of the office and into our homes. For some this...

The Lucid Group Thirsty Thursday: What’s in a story?

Yes, it’s that time of the month, a time everyone at Lucid has come to love and anticipate. Whether it’s sharing best practice, learning about new skills, gathering insights or...

For those who love science and storytelling — consider medical writing

In NetworkPharma’s latest career guide for wannabe medical writers, Kat Schleicher discusses how her love of science and storytelling makes medical writing the perfect career choice for her:​I love science!...

Lucid Group Elevates its Editorial Centre of Excellence – COMET

Lucid Group has been busy expanding and operationalising its editorial team – COMET (Centre Of Medical EdiTing) – to ensure its successful integration into Lucid Group. This has been achieved...

Lucid Group shine the spotlight on mental and physical health

Lucid kick-started its health and wellbeing agenda for the year with a focus on physical and mental wellbeing by taking inspiration from an elite sportsman, James Rodwell. James, a decorated...

It’s Teenage Kicks for Lucid Group

Lucid has been celebrating its 13th birthday this week. From New York to Singapore, Dubai, Macclesfield and London, teams have been gathering to celebrate the start of its teenage years.The...